Diagnostic evaluation of serum (1, 3)-β-d-glucan levels using the Fungitec G-Test MK kit for Pneumocystis jirovecii pneumonia (PCP) in non-HIV patients.

Pneumocystis jirovecii pneumonia (PCP) is an opportunistic and life-threatening pulmonary infection with an increasing prevalence among individuals who are human immunodeficiency virus (HIV)-negative. Evidence regarding diagnostic testing of PCP in this patient population is insufficient. We evaluated the performance of serum (1, 3)-β-d-glucan (BDG) using the Fungitec G-test MK kit for diagnosing PCP in non-HIV patients. We retrospectively analyzed data from 219 non-HIV adult patients who underwent bronchoscopy and were tested for P. jirovecii DNA by PCR using lavage samples from the lower respiratory tract. Fifty PCP patients and 125 non-PCP patients were included. The most common underlying diseases were malignancies and systemic autoimmune diseases. Using the serum BDG Fungitec G-test MK test to diagnose PCP, the area under the receiver operating characteristic curve (AUC) was 0.924, whereas the modified cut-off value of 36.6 pg/mL had a sensitivity and specificity of 92.0% and 84.8%, respectively. The AUC for patients with systemic autoimmune diseases was 0.873, and the accuracy of serum BDG test declined when using methotrexate (MTX). In conclusion, the serum BDG test was useful for diagnosing PCP in non-HIV patients; however, the results should be carefully interpreted in case of MTX administration. LAY SUMMARY The Fungitec G-test MK kit for measuring serum (1, 3)-β-d-glucan (BDG) levels had a sufficient diagnostic performance for Pneumocystis jirovecii pneumonia (PCP) in human immunodeficiency virus-negative patients. However, the results should be carefully interpreted in case of MTX administration.

[1]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Nikiphorou,et al.  Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. , 2019, Rheumatology.

[3]  H. Nakajima,et al.  Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[4]  N. E. Babady,et al.  Clinical Performance of (1,3) Beta-D-Glucan for the diagnosis of Pneumocystis Pneumonia in cancer patients tested with PCP PCR. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Lagrou,et al.  Beta-d-Glucan for Diagnosing Pneumocystis Pneumonia: a Direct Comparison between the Wako β-Glucan Assay and the Fungitell Assay , 2019, Journal of Clinical Microbiology.

[6]  J. Routy,et al.  Use of (1→3)‐β‐d‐glucan for diagnosis and management of invasive mycoses in HIV‐infected patients , 2018, Mycoses.

[7]  K. Shimada,et al.  Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum , 2018, Clinical Rheumatology.

[8]  U. Seybold,et al.  Evaluation of a Turbidimetric β-d-Glucan Test for Detection of Pneumocystis jirovecii Pneumonia , 2018, Journal of Clinical Microbiology.

[9]  Y. Yakushijin,et al.  A study on the colonization of Pneumocystis jirovecii among outpatients during cancer chemotherapy and among healthy smokers. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[10]  A. Hashimoto,et al.  Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis , 2017, International journal of rheumatology.

[11]  T. Walsh,et al.  Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses , 2017, International journal of molecular sciences.

[12]  Huiping Li,et al.  Evaluation of PCR in Bronchoalveolar Lavage Fluid for Diagnosis of Pneumocystis jirovecii Pneumonia: A Bivariate Meta-Analysis and Systematic Review , 2013, PloS one.

[13]  G. Nichols,et al.  Increasing Pneumocystis Pneumonia, England, UK, 2000–2010 , 2013, Emerging infectious diseases.

[14]  M. Finkelman,et al.  Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[15]  K. Nishimura,et al.  Diagnostic Accuracy of Serum 1,3-β-d-Glucan for Pneumocystis jiroveci Pneumonia, Invasive Candidiasis, and Invasive Aspergillosis: Systematic Review and Meta-Analysis , 2011, Journal of Clinical Microbiology.

[16]  H. Yazaki,et al.  Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Sugimoto,et al.  A Followup Study of Asymptomatic Carriers of Pneumocystis jiroveci During Immunosuppressive Therapy for Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[18]  J. Kalbfleisch,et al.  Serum Glucan Levels Are Not Specific for Presence of Fungal Infections in Intensive Care Unit Patients , 2003, Clinical Diagnostic Laboratory Immunology.

[19]  S. Oka,et al.  (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia , 1996, Clinical and diagnostic laboratory immunology.

[20]  S. Kohno,et al.  Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes , 1995, The Lancet.

[21]  R. Miller,et al.  Detection of Pneumocystis carinii with DNA amplification , 1990, The Lancet.

[22]  T. F. Smith,et al.  Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without AIDS , 1989 .

[23]  K. Atsuji,et al.  β-Glucan in Foods and Its Physiological Functions. , 2018, Journal of nutritional science and vitaminology.

[24]  M. Falagas,et al.  Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  J. V. van Dissel,et al.  β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. , 2011, The Journal of infection.

[26]  S. Koo,et al.  Role of (1-->3)-beta-D-glucan in the diagnosis of invasive aspergillosis. , 2009, Medical mycology.